Top-News
Donnerstag,
25.02.2021 22:35
von
PR Newswire
| Aufrufe: 72
Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
pixabay.com
PR Newswire
DUBLIN, Feb. 25, 2021
DUBLIN, Feb. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.
"I am proud of all that the Endo team achieved in a very challenging year. We made significant progress in advancing our strategic priorities, delivered solid financial performance, rapidly responded to the COVID-19 pandemic and advanced our ESG-related actions," said Blaise Coleman, President and Chief Executive Officer at Endo.
"Looking ahead, we remain committed to expanding and enhancing our portfolio through focused investments, including the anticipated spring 2021 launch of QWO®, the first and only FDA approved injectable treatment for cellulite. Together with our previously announced business transformation initiatives, we are confident that continuing to execute on our strategic priorities will enable us to deliver sustainable value over the long-term."
| FINANCIAL PERFORMANCE (in thousands, except per share amounts) | |||||||||||||||||||||
| | |||||||||||||||||||||
| | Three Months Ended December 31, | | | | Year Ended December 31, | | | ||||||||||||||
| | 2020 | | 2019 (1) | | Change | | 2020 | | 2019 (1) | | Change | ||||||||||
| Total Revenues, Net | $ | 760,221 | | | $ | 764,800 | | | (1) | % | | $ | 2,903,074 | | | $ | 2,914,364 | | | — | % |
| Reported Income (Loss) from Continuing Operations | $ | 141,247 | | | $ | (208,489) | | | NM | | | $ | 247,464 | | | $ | (360,584) | | | NM | |
| Reported Diluted Weighted Average Shares | 234,474 | | | 226,787 | | | 3 | % | | 233,653 | | | 226,050 | | | 3 | % | ||||
| Reported Diluted Net Income (Loss) per Share from Continuing Operations | $ | 0.60 | | | $ | (0.92) | | | NM | | | $ | 1.06 | | | $ | (1.60) | | | NM | |
| Reported Net Income (Loss) | $ | 119,343 | | | $ | (218,643) | | | NM | | | $ | 183,944 | | | $ | (422,636) | | | NM | |
| Adjusted Income from Continuing Operations (3) | $ | 175,995 | | | $ | 185,231 | | | (5) | % | | $ | 670,370 | | | $ | 616,078 | | | 9 | % |
| Adjusted Diluted Weighted Average Shares (2)(3) | 234,474 | | | 231,571 | | | 1 | % | | 233,653 | | | 231,706 | | | 1 | % | ||||
| Adjusted Diluted Net Income per Share from Continuing Operations (3) | $ | 0.75 | | | $ | 0.80 | | | (6) | % | | $ Werbung Mehr Nachrichten zur Endo Pharmaceuticals Holdings Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | |||||||||
